Shenzhen Chipscreen Biosciences Co., Ltd. (688321.SS)

17.60 -0.29 (-1.62%) At close: 03:00PM CST

Shenzhen Chipscreen Biosciences Co., Ltd.

Zhigu Industrial Park
21-24F, Block B 3157 Shahe West Road Nanshan District
Shenzhen 518057
China
86 755 2695 2070
https://www.chipscreen.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 1,057

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Xian-Ping Lu	Founder, Chairman, GM, CEO & President	N/A	N/A	1965
Mr. Jian-Xun Li BA.CFA	VP, Deputy GM, CFO & Director	N/A	N/A	1972
Dr. Desi Pan	VP, Deputy GM, Chief Scientific Officer and Head of the Early Research & Development Center	N/A	N/A	1971
Dr. Zhi-Bin Li Ph.D.	VP, Deputy GM and Head of Product Development & Production	N/A	N/A	1965
Mr. Liangji She	VP, Deputy GM & Head of Oncology Division	N/A	N/A	1966
Dr. Leming Shi	Co-Founder	N/A	N/A	N/A
Dr. Weiming Hu	Co-Founder	N/A	N/A	N/A
Ms. Ou Hai	VP, Deputy GM, Secretary of the Board, Head of Legal & Intellectual Property Department and Director	N/A	N/A	1980
Mr. Ji-Hui Yi MS	Vice President of Sales & Marketing	N/A	N/A	N/A
Mr. Libin Zhang	VP, Deputy GM & Head of Metabolic Diseases Division	N/A	N/A	1973

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CNY.

Description

Shenzhen Chipscreen Biosciences Co., Ltd. engages in the research, development, and sale of original small molecule drugs. The company develops precursor compounds and original new drug product lines for the treatment of human diseases in five therapeutic areas, including cancer, metabolic diseases, autoimmune disorders, central nervous system disorders, and antivirals. It is developing chidamide, a subtype-selective benzamide inhibitor of histone deacetylase (HDAC) primarily targeting subtypes 1, 2, 3 of class I HDAC; chiglitazar, a new-generation insulin sensitizing candidate drug for the treatment of type 2 diabetes mellitus; chiauranib, an aurora B/VEGFR/PDGFR /c-Kit/CSF1R inhibitor; and CS12192, a highly selective JAK3 kinase inhibitor. Shenzhen Chipscreen Biosciences Co., Ltd. was founded in 2001 and is headquartered in Shenzhen, China.

Corporate governance

Shenzhen Chipscreen Biosciences Co., Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.